Targets › ERAP1
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Apr 2028.
Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. (UniProt, Q9NZ08)
Open in Phaseline: the race on ERAP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Grey Wolf Therapeutics | GRWD0715 Selective ERAP1 inhibitor | ERAP1 | Phase 1 | Axial Spondyloarthritis (AxSpA) | Apr 2028 |
Axial Spondyloarthritis (AxSpA) (1)
small molecule (1)
Grey Wolf Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.